Change Language

Select Language

Global Autoinjector Market to Reach US$ 4.39 Billion by 2027, Propelled by Growing Prevalence of Chronic Diseases

Published on Nov 25, 2022

The latest report by IMARC Group, titled “Autoinjector Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2027,” finds that the global autoinjector market reached a value of US$ 1.65 Billion in 2021. An autoinjector is a self-injectable device having a pre-charged dosage of drugs. It delivers drugs through the subcutaneous or intramuscular route and offers several advantages, such as dosage accuracy, improved patient compliance, lower needlestick injuries, and enhanced efficiency of healthcare professionals. These devices are widely used during emergency conditions, such as migraine, anaphylaxis, status epilepticus, diabetes, psoriasis, multiple sclerosis, and rheumatoid arthritis. Owing to these properties, autoinjectors find extensive applications in hospitals, clinics, and home care centers across the globe.

Global Autoinjector Market Trends:

The market is primarily driven by the growing prevalence of asthma, arthritis, cancer, chronic obstructive pulmonary disease (COPD), and Alzheimer’s disease. In addition, the implementation of favorable government initiatives to promote the use of autoinjectors in schools represents another major growth-inducing factor. Besides this, key players are investing in research and development (R&D) activities to develop cost-effective and new technology-based autoinjectors for treating rheumatoid arthritis and multiple sclerosis. This, coupled with the rising awareness among individuals about the benefits of autoinjectors, is contributing to market growth. Moreover, the growing adoption of targeted therapies to alter proteins within cancer cells and prevent the formation of blood vessels in the tumor is also creating a favorable market outlook across the globe. Looking forward, IMARC Group expects the market to reach a value of US$ 4.39 Billion by 2027, exhibiting a CAGR of 16.70% during 2022-2027.

Market Summary:

  • Based on the type, the market has been categorized into disposable and reusable autoinjectors.
  • On the basis of the application, the market has been segregated into rheumatoid arthritis, anaphylaxis, multiple sclerosis, and others.
  • Based on the end user, the market has been bifurcated into home care settings, and hospitals and clinics.
  • Region-wise, the market has been divided into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has been examined in the report, with some of the key players being Amgen Inc., Antares Pharma Inc., Becton Dickinson and Company, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Haselmeier GmbH (Sulzer Ltd.), Johnson & Johnson, Mylan N.V. (Viatris Inc.), Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd., and Ypsomed Holding AG.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N Gould St, Ste 
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800


Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )

Drop us an email at